Vident Advisory’s Medpace MEDP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.35M Buy
4,428
+154
+4% +$71.1K 0.02% 633
2026
Q1
$2.05M Buy
4,274
+1,177
+38% +$603K 0.02% 618
2025
Q4
$1.74M Sell
3,097
-142
-4% -$80.6K 0.02% 619
2025
Q3
$1.67M Sell
3,239
-759
-19% -$331K 0.02% 629
2025
Q2
$1.25M Buy
3,998
+127
+3% +$38.1K 0.01% 656
2025
Q1
$1.18M Sell
3,871
-845
-18% -$284K 0.02% 663
2024
Q4
$1.57M Buy
4,716
+412
+10% +$140K 0.03% 481
2024
Q3
$1.44M Buy
4,304
+1,447
+51% +$550K 0.04% 507
2024
Q2
$1.18M Buy
2,857
+65
+2% +$25.7K 0.03% 537
2024
Q1
$1.13M Sell
2,792
-854
-23% -$300K 0.02% 540
2023
Q4
$1.12M Buy
3,646
+106
+3% +$28.6K 0.03% 529
2023
Q3
$857K Buy
+3,540
New +$905K 0.03% 558

Other funds holding MEDP

Vident Advisory's MEDP Position: Q2 2026 in Review

Vident Advisory increased its Medpace (MEDP) stake by 3.6% in Q2 2026, buying an estimated $71.1K and bringing the position to 4,428 shares worth $2.35M. The position accounts for 0.02% of the portfolio, ranked #633.

Vident Advisory first reported a position in MEDP in Q3 2023 and has held it in 12 quarters since. 700 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.

  • Vident Advisory held 4,428 shares of Medpace worth $2.35M as of Q2 2026.
  • Vident Advisory bought 154 Medpace shares in Q2 2026, an estimated $71.1K.
  • Medpace made up 0.02% of Vident Advisory's portfolio in Q2 2026, its #633 holding.
  • Vident Advisory first reported a position in Medpace in Q3 2023 and has held it in 12 quarters since.
  • 700 funds tracked by Wall St. Rank held Medpace as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.